Press releases

1 Sep 2026

UCB presents data at EEC 2026 highlighting continued leadership in epilepsy and developmental and epileptic encephalopathies

31 Aug 2026

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

31 Aug 2026

Transparency notification Wellington Management Group LLP

30 Jul 2026

UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase

8 Jul 2026

UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026

17 Jun 2026

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Press releases

Press releases

Search Press releases

UCB presents data at EEC 2026 highlighting continued leadership in epilepsy and developmental and epileptic encephalopathies

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

Transparency notification Wellington Management Group LLP

UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase

UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our 2026...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2025 - Direct access to our latest annual report

UCB Community Health Fund enters a new phase

UCBCares® - Discover what UCBCares® is about and the services they offer

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...

Strong Execution Fueling Sustained Company Growth

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment...

Strong Execution Fueling Sustained Company Growth

Innovation and Execution Power UCB’s Success

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB presents data at EEC 2026 highlighting continued leadership in epilepsy and developmental and epileptic encephalopathies

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

Transparency notification Wellington Management Group LLP

UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase

UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Choose a Country